Wedbush Remains a Hold on SAGE Therapeutics (SAGE)
Wedbush analyst Laura Chico maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $7.60.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Chico is a 2-star analyst with an average return of 0.0% and a 42.01% success rate. Chico covers the Healthcare sector, focusing on stocks such as Biogen, Neurocrine, and Travere Therapeutics.
In addition to Wedbush, SAGE Therapeutics also received a Hold from H.C. Wainwright’s Douglas Tsao in a report issued today. However, on the same day, Scotiabank maintained a Buy rating on SAGE Therapeutics (NASDAQ: SAGE).
SAGE market cap is currently $486.6M and has a P/E ratio of -1.18.
Read More on SAGE:
Disclaimer & DisclosureReport an Issue
- SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments
- Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects
- Sage Therapeutics Reports Strong Q1 2025 Performance
- Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties
- Sage Therapeutics reports Q1 EPS ($1.01), consensus ($1.01)
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.